GlassScriptPhysician profile
Sandeep Kapoor
NPI 1689860165
$5,299.07
in general payments reported to CMS, 2019-2025
18 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $780 · 2021: $999 · 2022: $1,073 · 2023: $635 · 2024: $904 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,462.79 | 2019-2025 | Injectafer |
| Collegium Pharmaceutical, INC. | $591.07 | 2020-2023 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $579.45 | 2019-2023 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $467.12 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $262.33 | 2020-2023 | Belsomra |
| Biodelivery Sciences International, INC. | $148.85 | 2019 | |
| Abbvie INC. | $144.56 | 2021-2023 | |
| Eisai INC. | $127.47 | 2020-2025 | |
| Allergan, INC. | $97.97 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $83.67 | 2023-2024 | Ingrezza |
| Novo Nordisk INC | $73.40 | 2021-2025 | Ozempic, Rybelsus |
| Ibsa Pharma INC. | $66.82 | 2022-2024 | Tirosint, Licart, Tirosint |
| Biofire Diagnostics, LLC | $55.62 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $49.83 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $27.01 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $21.46 | 2020 | |
| Horizon Therapeutics Plc | $20.38 | 2021 | |
| Pfizer INC. | $19.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.